Sun, Dec 28, 2014, 3:21 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. (FOLD) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • neiljshah neiljshah Jan 2, 2013 6:59 PM Flag

    Amicus Conference 1/9/2013

    I don't think so. People sometime even post profanity not sure why. You can argue about buy/sell but just posting insults and mouthing each other seems to prevailing on these boards.

    Sentiment: Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So neil, you propose a "Sell" rating on FOLD, can i have your thoughts on why? Not bashing, just want a normal person's opinion.

      • 5 Replies to tumbleyguy
      • I'm a buyer. Charts don't lie. I see this puppy breaking past $4 by earnings date

        Sentiment: Buy

      • Neil, but wouldn't you want to short it BEFORE the negative trials? I think those negative trials have been priced in already. The company is loaded with cash, little debt, huge pharma backing in GSK, and has other drugs in the pipeline. They aren't going bankrupt anytime soon. They were also downgraded by many firms after their failure. Most times I see that as a way for institutes to make money shorting, and after it didn't dip further, I don't see this going back down. I say cover before you lose more money. If you are short at this point. Hey, thats just my opinion though. I think it may be manipulation as well with the negative trials. How did a huge company put so many women into a huge trial like that without knowing what some of the consequences would be. I am wondering if GSK is looking into a buyout now or buying more shares in the future, knowing full well the drug still works, as does their chaperone system.

      • Yuppy, The stock was only at 5$ before their failed trials were publicly released, I don't know if it has the power to break 4 before they release any new positive info on those trials.

      • My reason is 1) result was not good.
        2) if result are going to be good for 1 full year and if they deliberately released this data so price can come down which will allows glaxo to invest more at discounted price then company is thinking more about top management rather than doing what is right.

        So basically If data is right then we should stay away and if its cooked up data for manipulation normal person who invest in stock for long term growth should definitely should stay away.

        Sentiment: Sell

      • I did not buy to short. I buy something for 1 year expecting more return than bank. My expectation is at least 5-10 % return at end of one year. Nothing more.

        I bought this at 5.23 and I am not hopeful about this returning to 5 level in near to 6 month.
        I am hoping if it goes about 3.50 i will book loss and get out of it. I had the same experience in Citi i bought at 46.7 (4.67 then they reverse split 1:10) i sold it at 25 in last July it is still not back at 46 level i was hoping to cover my loss of citi with this but i got into even deeper hole.

        Sentiment: Sell

8.18+0.24(+3.02%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Fluor Corporation
NYSEFri, Dec 26, 2014 4:03 PM EST